These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 11271797)

  • 1. Immunohistochemical demonstration of oestrogen and progesterone receptors.
    Cross SS
    J Clin Pathol; 2001 Jan; 54(1):78-9. PubMed ID: 11271797
    [No Abstract]   [Full Text] [Related]  

  • 2. Adverse effects of dyes used in sentinel node biopsy on immunocytochemical determination of hormone receptors in breast cancer cells.
    Masannat YA; Shaaban AM; Speirs V; Coast G; Jackson P; Horgan K; Hanby AM
    J Clin Pathol; 2007 Jun; 60(6):730-2. PubMed ID: 17557875
    [No Abstract]   [Full Text] [Related]  

  • 3. Quality control for the immunohistochemical demonstration of oestrogen and progesterone receptors.
    Nicholson RI; Leake R
    J Clin Pathol; 2000 Apr; 53(4):247. PubMed ID: 10823118
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
    Howell SJ; Wardley AM; Armstrong AC
    J Natl Cancer Inst; 2009 Dec; 101(24):1730; author reply 1730-1. PubMed ID: 19893007
    [No Abstract]   [Full Text] [Related]  

  • 5. [Laboratory's function in clinic practice of breast cancer].
    Sanz Casla MT; Maestro de las Casas ML
    Med Clin (Barc); 2003 Mar; 120(9):342-8. PubMed ID: 12646112
    [No Abstract]   [Full Text] [Related]  

  • 6. The Impact of Ki-67 on Immunostaining in Classification of Luminal Subtypes of breast Cancer.
    Lagios MD
    Breast J; 2015; 21(5):463-4. PubMed ID: 26332073
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinico-morphological significance of spontaneous necrosis in breast cancer].
    Kriuchkov AN
    Vopr Onkol; 2007; 53(2):229-34. PubMed ID: 17663181
    [No Abstract]   [Full Text] [Related]  

  • 8. Understanding Oestrogen Receptor Function in Breast Cancer and its Interaction with the Progesterone Receptor. New Preclinical Findings and their Clinical Implications.
    Baird RD; Carroll JS
    Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):1-3. PubMed ID: 26548499
    [No Abstract]   [Full Text] [Related]  

  • 9. The oestrogen receptor-negative/progesterone receptor-positive breast tumour: a biological entity or a technical artefact?
    Rhodes A; Jasani B
    J Clin Pathol; 2009 Jan; 62(1):95-6. PubMed ID: 19103868
    [No Abstract]   [Full Text] [Related]  

  • 10. Few positives for triple-negative breast cancer.
    Hede K
    J Natl Cancer Inst; 2011 Apr; 103(7):532-3. PubMed ID: 21436063
    [No Abstract]   [Full Text] [Related]  

  • 11. IMMUNOHISTOCHEMICAL ANALYSIS OF MAMMARY EPITHELIAL CELLS AT TUMORAL GROWTH IN REPUBLIC OF SAKHA (YAKUTIA).
    Kirillina MP; Loskutova KS; Lushnikova EL; Nepomnyaschih LM
    Wiad Lek; 2015; 68(4):537-42. PubMed ID: 26887131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers.
    Bidard FC; Conforti R; Boulet T; Michiels S; Delaloge S; André F
    Ann Oncol; 2007 Jul; 18(7):1285-6. PubMed ID: 17675400
    [No Abstract]   [Full Text] [Related]  

  • 13. Prognostic significance of oestrogen receptor beta in breast cancer.
    Palmieri C
    Br J Surg; 2000 Sep; 87(9):1248-9. PubMed ID: 10971439
    [No Abstract]   [Full Text] [Related]  

  • 14. Steroid receptors in pleural effusions of advanced breast cancer patients.
    Branković-Magić M; Nesković-Konstantinović Z; Nikolić-Vukosavljević D; Spuzić I
    Int J Biol Markers; 1995; 10(3):143-8. PubMed ID: 8551056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letter to the Editor regarding the paper by Aurilio et al., A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases.
    Ieni A; Barresi V; Giuffrè G; Caltabiano R; Cascone A; Del Sordo R; Cabibi D; Zeppa P; Lanzafame S; Sidoni A; Franco V; Tuccari G
    Eur J Cancer; 2014 Mar; 50(5):1035-7. PubMed ID: 24491394
    [No Abstract]   [Full Text] [Related]  

  • 16. Risk factors for breast cancer in young women by oestrogen receptor and progesterone receptor status.
    McCredie MR; Dite GS; Southey MC; Venter DJ; Giles GG; Hopper JL
    Br J Cancer; 2003 Nov; 89(9):1661-3. PubMed ID: 14583766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker assessment and molecular testing for prognostication in breast cancer.
    Kos Z; Dabbs DJ
    Histopathology; 2016 Jan; 68(1):70-85. PubMed ID: 26768030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IMMUNOHISTOCHEMICAL AND BIOCHEMICAL ANALYSIS OF MAMMARY GLAND TUMOURS OF DIFFERENT AGE PATIENTS.
    Lykholat T; Lykholat O; Antonyuk S
    Tsitol Genet; 2016; 50(1):40-51. PubMed ID: 27266184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leiomyoma of the nipple, and normal subareolar muscle fibres, are oestrogen and progesterone receptor positive.
    Chaudhary KS; Shousha S
    Histopathology; 2004 Jun; 44(6):626-8. PubMed ID: 15186281
    [No Abstract]   [Full Text] [Related]  

  • 20. How to measure and report the estrogen (and progesterone) receptor in breast cancer.
    Vermeulen PB; Van Laere SL; Dirix LY
    Int J Gynecol Cancer; 2006; 16 Suppl 2():529-32. PubMed ID: 17010066
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.